Open Payments

Childrens Hospital Los Angeles

Type
Teaching hospital
Where
Los Angeles, CA
Medicare CCN
053302
Received
$6,875,095 in 1,180 records, 2020 ($326,055 general, $6,549,039 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2020General payment37$326,055
2020Research payment1,143$6,549,039

By company

CompanyRecordsAmountYears
Amgen Inc.17$977,9702020
Eli Lilly and Company8$664,8442020
PFIZER INC.36$632,2042020
Takeda Pharmaceuticals U.S.A., Inc.55$478,3442020
Adaptive Biotechnologies Corporation654$364,5002020
GW Research Limited2$315,7982020
Grifols Shared Services North America, Inc.1$282,5582020
Novartis Pharmaceuticals Corporation9$238,2612020
Gilead Sciences, Inc.25$218,7592020
United Therapeutics Corporation14$207,8262020
Novo Nordisk AS69$167,5292020
AstraZeneca UK Limited3$153,8762020
Sarepta Therapeutics, Inc.7$144,4942020
JAZZ PHARMACEUTICALS INC.3$139,8112020
Becton, Dickinson and Company3$139,4152020
Ultragenyx Pharmaceutical Inc.7$120,6612020
Genentech, Inc.10$117,0012020
Celgene Corporation5$115,2282020
UCB Biosciences Inc.3$114,3412020
VERTEX PHARMACEUTICALS INCORPORATED3$111,0332020
BioFire Diagnostics, LLC17$108,6952020
KLS-Martin L.P.4$100,0002020
Regeneron Pharmaceuticals, Inc.24$78,2822020
AstraZeneca Pharmaceuticals LP3$57,6152020
E.R. Squibb & Sons, L.L.C.3$52,1632020
Neurelis, Inc.3$51,6162020
Kite Pharma, Inc.5$46,2132020
Merck Sharp & Dohme LLC18$45,7532020
AQUESTIVE THERAPEUTICS, INC.2$45,0142020
Aurobindo Pharma USA, Inc.3$43,2502020
Spark Therapeutics, Inc.5$37,8732020
Biotest AG4$37,5152020
CSL Behring1$37,5002020
BIOVERATIV THERAPEUTICS INC.6$37,2312020
ABBVIE INC.5$33,0392020
Incyte Corporation26$30,0232020
Daiichi Sankyo Inc.16$27,6472020
GENZYME CORPORATION2$25,5462020
SANOFI US SERVICES INC.2$24,2602020
Mallinckrodt Hospital Products Inc.3$20,0562020
Alexion Pharmaceuticals, Inc.1$19,9352020
LEO Pharma AS1$17,7202020
Mannkind Corporation16$17,0532020
PTC Therapeutics, Inc.4$16,8282020
Astellas Pharma Global Development3$16,4002020
BioMarin Pharmaceutical Inc.9$15,7322020
Luminex Corporation2$15,3252020
ARRAY BIOPHARMA INC2$14,1432020
Masimo Corporation4$12,9042020
Dexcom, Inc.5$12,5472020

By nature of payment

NatureRecordsAmount
Research payment1,143$6,549,039
Grant18$300,796
Compensation for serving as faculty or as a speaker for an accredited or certified continuing educat2$15,325
Space rental or facility fees (teaching hospital only)4$4,075
Honoraria1$2,191
Education2$1,771
Charitable Contribution3$1,107
Gift4$697
Royalty or License3$91

Records

DateCompanyAmountNatureFormProductStudyYear
2020-12-31Ultragenyx Pharmaceutical Inc.$14,810Research paymentCash or cash equivalentDOJOLVI Drug, Oral nutritional supplementsUX007-CL0032020
2020-12-31AstraZeneca UK Limited$6,123Research paymentIn-kind items and servicesBYDUREON Drug, Cardiovascular and MetabolismA Phase 3 Double Blind Placebo Controlled Randomized Multi Center Study To Assess the Safety and Efficacy of Exenatide O2020
2020-12-31AstraZeneca Pharmaceuticals LP$3,891Research paymentIn-kind items and servicesA Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Anti2020
2020-12-31Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-31Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-31Masimo Corporation$46EducationIn-kind items and servicesSET and rainbow SET Device, Devices2020
2020-12-31Aimmune Therapeutics, Inc.$18Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2020
2020-12-31Stryker Corporation$16GiftCash or cash equivalentNONE Device, NONE2020
2020-12-29Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-29Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-29Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-28Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-28Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-28Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-28Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-28Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-28Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-28Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-27Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-25Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-23Gilead Sciences, Inc.$2,868Research paymentCash or cash equivalentVemlidy Drug, HBVA Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala2020
2020-12-23Gilead Sciences, Inc.$2,280Research paymentCash or cash equivalentSovaldi Drug, HCVA Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf2020
2020-12-23Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-23Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-23Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-23Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-23Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-22Novo Nordisk AS$23,967Research paymentCash or cash equivalentVictoza Biological, DiabetesNN2211-36592020
2020-12-22SANOFI US SERVICES INC.$8,310Research paymentCash or cash equivalentATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inh2020
2020-12-22Daiichi Sankyo Inc.$5,875Research paymentCash or cash equivalentSavaysa Drug, ThrombosisDU176B-D-3122020
2020-12-22Daiichi Sankyo Inc.$1,533Research paymentCash or cash equivalentSavaysa Drug, ThrombosisDU176B-D-3122020
2020-12-22Novo Nordisk AS$1,500Research paymentCash or cash equivalentVictoza Biological, DiabetesNN2211-36592020
2020-12-22Daiichi Sankyo Inc.$1,421Research paymentCash or cash equivalentSavaysa Drug, ThrombosisDU176B-D-3122020
2020-12-22Novo Nordisk AS$1,351Research paymentCash or cash equivalentSogroya Biological, Growth HormoneNN8640-42632020
2020-12-22Novo Nordisk AS$1,000Research paymentCash or cash equivalentVictoza Biological, DiabetesNN2211-36592020
2020-12-22Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-22Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-22Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-21Boston Scientific Corporation$200Charitable ContributionCash or cash equivalent2020
2020-12-21Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-21Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-21Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-20Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-18Neurelis, Inc.$8,957Research paymentCash or cash equivalentVALTOCO Drug, EPILEPSYA 12-Month, Open Label, Repeat-Dose Safety Study Of NRL-1IN Epilepsy Subjects2020
2020-12-18Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-17PTC Therapeutics, Inc.$4,711Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ATALUREN IN PATIENTS WITH NONSENSE 2020
2020-12-17Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-17Boston Scientific Corporation$200Charitable ContributionCash or cash equivalent2020
2020-12-17Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-16Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-16Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-16Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-16Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-15Luminex Corporation$2,700Compensation for serving as faculty or as a speaker for an accredited or certified continuing educatCash or cash equivalent2020
2020-12-15PFIZER INC.$1,727Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYAN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH 2020
2020-12-15PFIZER INC.$397Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYAN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH 2020
2020-12-15Amgen Inc.$183Research paymentIn-kind items and servicesProlia Biological, Bone HealthGIOP Pediatric 12020
2020-12-14Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-14Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-13Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-12Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-11Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-11Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-11Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-11Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-10AQUESTIVE THERAPEUTICS, INC.$16,470Research paymentCash or cash equivalentLIBERVANT Drug, EpilepsySAFETY AND TOLERABILITY STUDY OF DIAZEPAM BUCCAL SOLUBLE FILM DBSF IN SUBJECTS WITH EPILEPSY2020
2020-12-10BioFire Diagnostics, LLC$2,639Research paymentIn-kind items and servicesFilmArray System Device, Clinical DiagnosticsBioFire PN1.x Prospective Study2020
2020-12-10Regeneron Pharmaceuticals, Inc.$1,995Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <2020
2020-12-10Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-10Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-10Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-10Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-10Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-10Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-09Genentech, Inc.$31,287Research paymentCash or cash equivalentHEMLIBRA Biological, HematologySTUDY TO EVALUATE THE SAFETY EFFICACY PK AND PD OF EMICUZUMAB IN MILD OR MODERATE HEMOPHILIA A NI2020
2020-12-09Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-09Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-09Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-09Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-09Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-08Takeda Pharmaceuticals U.S.A., Inc.$50,369Research paymentCash or cash equivalentGATTEX Drug, INTERNAL MEDICINEA RETROSPECTIVE AND PROSPECTIVE, OPEN LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF TEDUGLUTIDE IN PEDIATRIC PATIENTS WI2020
2020-12-08Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-08Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-08Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-08Incyte Corporation$42Research paymentCash or cash equivalentA Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub2020
2020-12-08Incyte Corporation$24Research paymentCash or cash equivalentA Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub2020
2020-12-08Incyte Corporation$24Research paymentCash or cash equivalentA Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub2020
2020-12-08Incyte Corporation$24Research paymentCash or cash equivalentA Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub2020
2020-12-08Incyte Corporation$20Research paymentCash or cash equivalentA Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub2020
2020-12-07Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-07Amgen Inc.$183Research paymentIn-kind items and servicesProlia Biological, Bone HealthGIOP Pediatric 12020
2020-12-07Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-07Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-06Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-06Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-06Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-05Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-04Genentech, Inc.$22,345Research paymentCash or cash equivalentHEMLIBRA Biological, HematologyCOMPARISON OF BYPASSING AGENTS FEIBA RFVIIA IN PATIENTS ON EMICIZUMAB USING GLOBAL HEMOSTASIS ASSA2020
2020-12-04Merck Sharp & Dohme LLC$2,027Research paymentIn-kind items and servicesZINPLAVA Biological, INFECTIOUS DISEASEProtocol Title A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Phar2020
2020-12-03PFIZER INC.$30,093Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYAN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH 2020
2020-12-03Amgen Inc.$550Research paymentIn-kind items and servicesProlia Biological, Bone HealthPediatric OI.2020
2020-12-03Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-03Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-03Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-03PFIZER INC.$298Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYAN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH 2020
2020-12-03Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-03Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-02Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-12-02ABBVIE INC.$50Research paymentCash or cash equivalentHUMIRA Biological, IMMUNOLOGYP11-2922020
2020-12-01Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-30Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-30Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-28Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-28Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-27Kite Pharma, Inc.$9,706Research paymentCash or cash equivalentA Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with R2020
2020-11-27Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-27Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-27Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-26Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-26Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-26Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-25Novo Nordisk AS$1,729Research paymentCash or cash equivalentSogroya Biological, Growth HormoneNN8640-42632020
2020-11-25Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-25Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-25Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-25Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-24Sarepta Therapeutics, Inc.$10,237Research paymentCash or cash equivalentVyondys 53 Drug, Genetic Disease4045-3012020
2020-11-24Spark Therapeutics, Inc.$4,577Research paymentCash or cash equivalentLUXTURNA Biological, OCULARA POST-AUTHORIZATION, MULTICENTER, LONGITUDINAL, OBSERVATIONAL SAFETY REGISTRY STUDY FOR PATIENTS TREATED WITH VORETIGEN2020
2020-11-24Regeneron Pharmaceuticals, Inc.$2,589Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <2020
2020-11-24Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-23Ultragenyx Pharmaceutical Inc.$28,373Research paymentCash or cash equivalentCrysvita Drug, XLH Metabolic Bone DisorderUX023-CL4012020
2020-11-23Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-23Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-23Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-20Adaptive Biotechnologies Corporation$26,100Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAONC14012020
2020-11-20Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-20Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAONC14012020
2020-11-20Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-20Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-20Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-19JAZZ PHARMACEUTICALS INC.$72,500Research paymentCash or cash equivalentAN OPEN-LABEL STUDY OF JZP-458 (RC-P) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)/LYMPHOBLASTIC LYMPHOMA (LBL)2020
2020-11-19JAZZ PHARMACEUTICALS INC.$16,500Research paymentCash or cash equivalentAN OPEN-LABEL STUDY OF JZP-458 (RC-P) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)/LYMPHOBLASTIC LYMPHOMA (LBL)2020
2020-11-19Abbott Laboratories$1,175Research paymentCash or cash equivalentSJM Masters HP 15mm Rotatable Mechanical Heart Valve Device, Cardiac Arrhythmias and Heart FailureA Single Arm, Non-randomized, Multi-center Clinical Study of the SJM Masters HP 15mm Rotatable Mechanical Heart Valve as2020
2020-11-19Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase I,II Study of Pembrolizumab MK-3475 in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or2020
2020-11-19Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-18Genentech, Inc.$10,921Research paymentCash or cash equivalentHEMLIBRA Biological, HematologyOPEN LABEL PHASE III STUDY OF EMICIZUMAB IN HEMOPHILIA A PEDIATRICS PATIENTS WITH INHIBITORS2020
2020-11-18Gilead Sciences, Inc.$1,520Research paymentCash or cash equivalentSovaldi Drug, HCVA Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf2020
2020-11-18Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-17Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-17Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-17Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-17Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-17Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-17Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-16Ultragenyx Pharmaceutical Inc.$9,679Research paymentCash or cash equivalentCrysvita Drug, XLH Metabolic Bone DisorderUX023-CL4012020
2020-11-16Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-16Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-16Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-16EMD Millipore Corporation$41Royalty or LicenseCash or cash equivalent Device, DIAGNOSTIC TESTING2020
2020-11-15Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-15Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-14Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-14Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-13JAZZ PHARMACEUTICALS INC.$50,811Research paymentIn-kind items and servicesVYXEOS Drug, HEMATOLOGY/ONCOLOGYA STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED A2020
2020-11-13Genentech, Inc.$24,938Research paymentCash or cash equivalentHEMLIBRA Biological, HematologySTUDY TO EVALUATE THE SAFETY EFFICACY PK AND PD OF EMICUZUMAB IN MILD OR MODERATE HEMOPHILIA A NI2020
2020-11-12Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-12Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-12Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-12Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-12Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-11Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$5,292Research paymentCash or cash equivalentZOLGENSMA Biological, GENE THERAPYA Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy2020
2020-11-11Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$1,883Research paymentCash or cash equivalentZOLGENSMA Biological, GENE THERAPYA Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy2020
2020-11-10PFIZER INC.$8,240Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYAN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH 2020
2020-11-10PFIZER INC.$2,672Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYAN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH 2020
2020-11-10PFIZER INC.$1,727Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYAN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH 2020
2020-11-10Genentech, Inc.$1,549Research paymentCash or cash equivalentHEMLIBRA Biological, HematologyEMICIZUMAB MINOR SURGERY2020
2020-11-10PFIZER INC.$1,407Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYAN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH 2020
2020-11-10PFIZER INC.$496Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYAN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH 2020
2020-11-10Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-10Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-10Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-10Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-10PFIZER INC.$221Research paymentIn-kind items and servicesIBRANCE Drug, ONCOLOGYAN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH 2020
2020-11-10Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-09Novartis Pharmaceuticals Corporation$833Research paymentIn-kind items and servicesKYMRIAH Biological, ONCOLOGYPHASE II PEDIATRIC RELAPSED AND OR REFRACTORY ALL CONFIRMATORY2020
2020-11-09Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-09Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-09Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-09Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-09Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-09Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-08Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-08Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-08Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-08Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-06Takeda Pharmaceuticals U.S.A., Inc.$1,929Research paymentCash or cash equivalentOPEN LABEL STUDY OF THE EFFICACY AND LONG TERM SAFETY OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBI2020
2020-11-06Adaptive Biotechnologies Corporation$450Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020
2020-11-05Epizyme, Inc.$6,357Research paymentCash or cash equivalentTAZVERIK Drug, ONCOLOGYA PHASE 1 STUDY OF THE EZH2 INHIBITOR TAZEMETOSTAT IN PEDIATRIC SUBJECTS WITH RELAPSED OR REFRACTORY INI1-NEGATIVE TUMOR2020
2020-11-05Regeneron Pharmaceuticals, Inc.$2,000Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <2020
2020-11-05Adaptive Biotechnologies Corporation$150Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAPBMTC-ONC-17012020

The latest 200 records of 1,180.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Los Angeles CountyLos Angeles city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Los Angeles, CA, county Los Angeles County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Los Angeles, CA
County
Los Angeles County, CA
State
California
Population B010033,857,2639,808,66739,287,377
Population, 2020 census P13,898,74710,014,00939,538,223
Median age B0100237.238.237.9
Under 18 B0100119.2%20.6%22.0%
65 and over B0100114.2%15.2%15.7%
Households B110011,439,0973,416,44913,548,091
Foreign born B0500235.7%33.4%27.0%
Median household income B19013$81,939$90,112$99,122
Median family income B19113$94,546$101,573$113,346
Per capita income B19301$47,685$45,792$49,513
Poverty rate B1700116.5%13.7%12.0%
Unemployment rate B230258.2%7.3%6.6%
Civilian labor force B230252,128,9185,200,65620,068,466
Mean commute (minutes) B0801330.730.428.7
Bachelor's degree or higher B1500338.5%36.0%37.1%
Housing units B250011,554,3323,650,46614,644,735
Owner-occupied B2500336.0%45.9%55.9%
Renters B2500364.0%54.1%44.1%
Median home value B25077$921,200$834,200$734,700
Median gross rent B25064$1,933$1,954$2,036
White, not Hispanic B0300228.1%24.7%33.8%
Black B030028.1%7.4%5.2%
Hispanic or Latino B0300247.2%48.4%40.2%
Asian B0300211.9%14.9%15.3%
American Indian and Alaska Native B030020.1%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Los Angeles, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.